Last reviewed · How we verify

NCT07372729

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

Recruiting now NA Last updated 6 April 2026
What this trial tests

NA trial testing Smartwatch-Based Multi-Faceted Behavioral Intervention Model Led by Exercise and Dietary Interventions, Supported by Primary Medical Staff, Along with the Distribution of Health Education Manuals in Prehypertension in 1,400 participants. Currently enrolling.

Timeline
15 March 2026
Primary endpoint
15 September 2026
15 March 2027

Quick facts

Lead sponsorBeijing Anzhen Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment1,400
Start date15 March 2026
Primary completion15 September 2026
Estimated completion15 March 2027
Sites3 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Anzhen Hospital

Who can join

18 and older, any sex, with Prehypertension or Borderline Dyslipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among Overweight/Obese Individuals with Cardiometabolic Preconditions, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prehypertension

Currently open trials in the same condition.

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07372729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing